Kyprolis comes as an injection that is given intravenously to help treat a type of cancer called multiple myeloma. This prescription medicine is specifically designed for people who have tried at least two other medications but the cancer has still progressed. It is given once a day for two days in a row each week. Side effects are common and include nausea, fatigue, and anemia.
Kyprolis™ (carfilzomib) is a prescription medication approved to treat multiple myeloma, a cancer of the plasma cells, a type of white blood cell found in the bone marrow. It is for use in people whose cancer progressed after treatment with at least two other medications. Kyprolis belongs to a group of medicines known as proteasome inhibitors.
Kyprolis is made by DSM Pharmaceuticals, Inc., for Onyx Pharmaceuticals, Inc.
Kyprolis has been studied in people with multiple myeloma whose disease had become worse after treatment with at least two other anticancer medications. All of the people in the study had previously been treated with medications known as bortezomib (Velcade®) and thalidomide (Thalomid®).
In this study, 22.9 percent of people had a complete or partial disappearance of their tumors after Kyprolis treatment. The study did not evaluate whether the medicine reduced symptoms or helped people live longer.
As mentioned previously, Kyprolis belongs to a group of medicines known as proteasome inhibitors. Proteasomes are proteins found inside healthy cells and cancerous cells. One of their actions is to break down abnormal or unneeded proteins. Proteasome inhibitors, such as Kyprolis, block the action of proteasomes and prevent them from breaking down proteins. As a result, proteins build up in cells, causing the cells to die.
Kyprolis can kill both cancer cells and healthy cells, which is what causes many of the dangerous side effects. However, it has a greater effect on cells that rapidly multiply. Generally, cancer cells multiply more rapidly than healthy cells and are, therefore, more affected by Kyprolis treatment.